Brief: Outlook Therapeutics Submits Type A Meeting Request To FDA Following Complete Response Letter
11/02/2026 14:53
Feb 11 (Reuters) - Outlook Therapeutics Inc OTLK.O: OUTLOOK THERAPEUTICS SUBMITS TYPE A MEETING REQUEST TO FDA FOLLOWING COMPLETE RESPONSE LETTER OUTLOOK THERAPEUTICS INC: INTENDS TO CONTINUE TO WORK WITH FDA ON A PATH FORWARD FOR RESOLVING FDA'S REQUEST FOR ADDITIONAL CONFIRMATORY EVIDENCE Source text: ID:nGNX5cKnKq Further company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce